New combo tackles tough colorectal cancer

NCT ID NCT01715441

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether combining two drugs, sorafenib and irinotecan, works better than either drug alone in people with advanced colorectal cancer that has a KRAS mutation and has stopped responding to all standard treatments. The study enrolled 173 participants across multiple centers. The main goal was to see how many patients had their cancer stop growing after two months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sorafenib and irinotecan combination
What this could lead to
If successful, this combination could offer a new treatment option for people with a hard-to-treat form of colorectal cancer that has stopped responding to other drugs.
What could go wrong
This is a phase 2 trial with a moderate number of participants, so results are not definitive. The combination may not improve outcomes over single drugs and could cause additional side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER PATIENTS WITH KRAS MUTATED TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • C.H.U. de REIMS

    Reims, 51092, France

  • CHU Charles Nicolle

    Rouen, 76038, France

  • CRLC Val d'Aurelle-Paul Lamarque

    Montpellier, 34298, France

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Hôpital AVICENNE

    Bobigny, 93009, France

  • Hôpital LA TIMONE

    Marseille, 13365, France

  • Institut de Cancérologie de l'Ouest - René Gauducheau

    Saint-Herblain, 44805, France